Correction: Evaluation of tenascin-C by tenatumomab in T-cell non-Hodgkin lymphomas identifies a new target for radioimmunotherapy

PDF  |  How to cite

Oncotarget. 2018; 9:17256-17256. https://doi.org/10.18632/oncotarget.25064

Metrics: PDF 1572 views  |   ?  

Giuseppe Gritti1, Andrea Gianatti2, Fiorella Petronzelli3, Rita De Santis3, Chiara Pavoni1, Riccardo Lorenzo Rossi4, Laura Cattaneo2, Luigi Giusto Spagnoli5, Silvia Ferrari1, Andrea Rossi1, Anna Maria Barbui1 and Alessandro Rambaldi1,6

1Hematology and Bone Marrow Transplant Units, Ospedale Papa Giovanni XXIII, Bergamo, Italy
2Pathology Unit, Ospedale Papa Giovanni XXII, Bergamo, Italy
3Sigma Tau S.p.A. Biotech Products R and D, Pomezia, Italy
4Bioinformatics, Istituto Nazionale Genetica Molecolare, Milan, Italy
5Department of Biomedicine and Prevention, Università di Roma Tor Vergata, Rome, Italy
6Department of Oncology and Oncohematology, Università degli Studi di Milano, Milan, Italy

Published: March 30, 2018

This article has been corrected: The online version of figure 3 has been corrected:

Original article: Oncotarget. 2018; 9:9766-9775 DOI: https://doi.org/10.18632/oncotarget.23919.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 25064